JP2007523631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523631A5 JP2007523631A5 JP2006541469A JP2006541469A JP2007523631A5 JP 2007523631 A5 JP2007523631 A5 JP 2007523631A5 JP 2006541469 A JP2006541469 A JP 2006541469A JP 2006541469 A JP2006541469 A JP 2006541469A JP 2007523631 A5 JP2007523631 A5 JP 2007523631A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarker
- pancreatic adenocarcinoma
- sample
- subject
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 114
- 239000000090 biomarker Substances 0.000 claims 106
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 93
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 93
- 239000000523 sample Substances 0.000 claims 68
- 230000000694 effects Effects 0.000 claims 59
- 108090000623 proteins and genes Proteins 0.000 claims 52
- 150000001875 compounds Chemical class 0.000 claims 45
- 238000010171 animal model Methods 0.000 claims 42
- 239000000203 mixture Substances 0.000 claims 36
- 102000004169 proteins and genes Human genes 0.000 claims 30
- 238000012360 testing method Methods 0.000 claims 30
- 108091033319 polynucleotide Proteins 0.000 claims 20
- 102000040430 polynucleotide Human genes 0.000 claims 20
- 239000002157 polynucleotide Substances 0.000 claims 20
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 19
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 19
- 230000014509 gene expression Effects 0.000 claims 19
- 102100030708 GTPase KRas Human genes 0.000 claims 12
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 230000003213 activating effect Effects 0.000 claims 12
- 230000035772 mutation Effects 0.000 claims 12
- 239000003153 chemical reaction reagent Substances 0.000 claims 10
- 238000002560 therapeutic procedure Methods 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 238000012423 maintenance Methods 0.000 claims 5
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims 4
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 4
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000009396 hybridization Methods 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- 238000006452 multicomponent reaction Methods 0.000 claims 4
- 210000004923 pancreatic tissue Anatomy 0.000 claims 4
- 230000009261 transgenic effect Effects 0.000 claims 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 3
- 101710102803 Tumor suppressor ARF Proteins 0.000 claims 3
- 210000000941 bile Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 230000000711 cancerogenic effect Effects 0.000 claims 3
- 231100000315 carcinogenic Toxicity 0.000 claims 3
- 210000003608 fece Anatomy 0.000 claims 3
- 230000000977 initiatory effect Effects 0.000 claims 3
- 239000002853 nucleic acid probe Substances 0.000 claims 3
- 102200006539 rs121913529 Human genes 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 210000002700 urine Anatomy 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 241000283984 Rodentia Species 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 238000004891 communication Methods 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 238000011161 development Methods 0.000 claims 2
- 230000018109 developmental process Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 230000002974 pharmacogenomic effect Effects 0.000 claims 2
- 229940124606 potential therapeutic agent Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000003753 real-time PCR Methods 0.000 claims 2
- 230000011218 segmentation Effects 0.000 claims 2
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 101150008921 Brca2 gene Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108700005087 Homeobox Genes Proteins 0.000 claims 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 claims 1
- -1 Ink4a Proteins 0.000 claims 1
- 101150110531 MLH1 gene Proteins 0.000 claims 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 claims 1
- 101150040067 STK11 gene Proteins 0.000 claims 1
- 102000049937 Smad4 Human genes 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000000104 diagnostic biomarker Substances 0.000 claims 1
- 230000002183 duodenal effect Effects 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000000092 prognostic biomarker Substances 0.000 claims 1
- 230000004850 protein–protein interaction Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 238000007423 screening assay Methods 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 239000000225 tumor suppressor protein Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52546403P | 2003-11-26 | 2003-11-26 | |
| US60/525,464 | 2003-11-26 | ||
| PCT/US2004/039756 WO2005053512A2 (en) | 2003-11-26 | 2004-11-24 | Animal models of pancreatic adenocarcinoma and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007523631A JP2007523631A (ja) | 2007-08-23 |
| JP2007523631A5 true JP2007523631A5 (enExample) | 2008-01-17 |
| JP4733644B2 JP4733644B2 (ja) | 2011-07-27 |
Family
ID=34652344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541469A Expired - Fee Related JP4733644B2 (ja) | 2003-11-26 | 2004-11-24 | 膵臓腺癌の動物モデルおよびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080242742A1 (enExample) |
| EP (1) | EP1718192A4 (enExample) |
| JP (1) | JP4733644B2 (enExample) |
| CA (1) | CA2547355A1 (enExample) |
| WO (1) | WO2005053512A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005118869A2 (en) * | 2004-05-28 | 2005-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| EP2326734B1 (en) * | 2008-09-03 | 2016-11-09 | The Johns Hopkins University | Pathways underlying pancreatic tumorigenesis and an hereditary pancreatic cancer gene |
| US8420884B2 (en) * | 2008-10-16 | 2013-04-16 | Tufts Medical Center Inc. | Models of malignant brain cancer, and therapeutic siRNAs against oncogenic signaling pathways, and methods and kits for uses therefor |
| US8722964B2 (en) | 2009-04-23 | 2014-05-13 | Transposagen Biopharmaceuticals, Inc. | Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes |
| US8563711B2 (en) | 2009-06-01 | 2013-10-22 | Sungkyunkwan University Foundation For Corporate Collaboration | Nucleic acid aptamer capable of binding specifically to pancreatic cancer cells or tissues and use thereof |
| WO2010151789A1 (en) * | 2009-06-25 | 2010-12-29 | The Regents Of The University Of California | Salivary transcriptomic and microbial biomarkers for pancreatic cancer |
| WO2011002988A1 (en) | 2009-07-01 | 2011-01-06 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for severe combined immunodeficiency (scid) |
| AU2010282239A1 (en) * | 2009-08-14 | 2012-03-08 | Revivicor, Inc. | Multi-transgenic pigs for diabetes treatment |
| CA2825894C (en) * | 2011-02-02 | 2021-11-30 | Amgen Inc. | Prognosis of cancer using a circulating biomarker |
| RU2457546C1 (ru) * | 2011-03-09 | 2012-07-27 | Учреждение Российской академии медицинских наук Научный центр реконструктивной и восстановительной хирургии Сибирского отделения РАМН (НЦРВХ СО РАМН) | Способ моделирования аденокарциномы толстой кишки человека |
| CA2848162C (en) | 2011-09-12 | 2023-03-14 | Creatics Llc | Non-invasive methods of detecting target molecules |
| WO2013184905A1 (en) | 2012-06-06 | 2013-12-12 | Myriad Genetics, Inc. | Hereditary cancer genes |
| CA2902841A1 (en) * | 2013-03-13 | 2014-10-02 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| US10172333B2 (en) | 2013-03-15 | 2019-01-08 | Exemplar Genetics, Llc | Animal models of cancer |
| KR101456627B1 (ko) * | 2013-04-24 | 2014-11-03 | 국립암센터 | 면역 치료 및 위암 치료제에 대한 효능 및 독성 평가를 위한 마우스 위암 세포주 |
| US20150191744A1 (en) | 2013-12-17 | 2015-07-09 | University Of Massachusetts | Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling |
| US9986723B2 (en) * | 2014-10-22 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Screen and use of therapeutics for pancreatic ductal adenocarcinoma |
| JP6695586B2 (ja) * | 2015-12-17 | 2020-05-20 | 国立大学法人北海道大学 | 膵癌の再発リスクの予測に用いるための診断薬及びキット、並びに予測方法 |
| WO2018230970A1 (ko) | 2017-06-14 | 2018-12-20 | 서울대학교 산학협력단 | 돌연변이 마우스 유래 췌장 오거노이드 및 그 용도 |
| US20220033814A1 (en) * | 2018-12-03 | 2022-02-03 | Triplet Therapeutics, Inc. | Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh1 activity |
| CN114672517B (zh) * | 2020-12-24 | 2024-01-19 | 四川大学华西医院 | 一种全新基因组合模式在小鼠中建立胰腺癌的方法 |
| CN114651786B (zh) * | 2022-04-01 | 2023-05-26 | 广西医科大学 | 一种小鼠马尔尼菲篮状菌潜伏再激活模型的构建方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6033862A (en) | 1996-10-30 | 2000-03-07 | Tokuyama Corporation | Marker and immunological reagent for dialysis-related amyloidosis, diabetes mellitus and diabetes mellitus complications |
| CA2379819A1 (en) * | 1999-07-29 | 2001-02-08 | Dana-Farber Cancer Institute, Inc. | Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo |
| ES2312607T3 (es) * | 2001-03-28 | 2009-03-01 | Dana Farber Cancer Inst Inc | Identificacion y caracterizacion de genes. |
| JP2005523012A (ja) * | 2002-04-16 | 2005-08-04 | デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド | 癌モデル |
| EP1670308B9 (en) * | 2003-08-28 | 2012-11-14 | Aveo Pharmaceuticals, Inc. | Chimeric cancer models |
-
2004
- 2004-11-24 WO PCT/US2004/039756 patent/WO2005053512A2/en not_active Ceased
- 2004-11-24 JP JP2006541469A patent/JP4733644B2/ja not_active Expired - Fee Related
- 2004-11-24 CA CA002547355A patent/CA2547355A1/en not_active Abandoned
- 2004-11-24 EP EP04812305A patent/EP1718192A4/en not_active Withdrawn
-
2006
- 2006-08-11 US US11/503,499 patent/US20080242742A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007523631A5 (enExample) | ||
| Amundadottir | Pancreatic cancer genetics | |
| Keng et al. | A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma | |
| Daniotti et al. | BRAF alterations are associated with complex mutational profiles in malignant melanoma | |
| JP2010524427A (ja) | 慢性移植片機能障害のためのバイオマーカー | |
| AU2009270851A1 (en) | Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof | |
| US8168602B2 (en) | Compositions, kits and methods for identification, assessment, prevention and therapy of cancer | |
| Winter et al. | Mapping complex traits in a diversity outbred F1 mouse population identifies germline modifiers of metastasis in human prostate cancer | |
| JP2008512984A5 (enExample) | ||
| JP4733644B2 (ja) | 膵臓腺癌の動物モデルおよびその使用 | |
| Oh et al. | Single nucleotide polymorphisms of 8 inflammation‐related genes and their associations with smoking‐related cancers | |
| Flanagan et al. | Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features | |
| Webster et al. | The tumor suppressor BAP 1 cooperates with BRAFV 600E to promote tumor formation in cutaneous melanoma | |
| JP2007528707A (ja) | 統合失調症の診断および治療のための標的としてのｅｇｒ遺伝子 | |
| Lee et al. | Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis | |
| Schoultz et al. | Tissue specificity of oncogenic BRAF targeted to lung and thyroid through a shared lineage factor | |
| Rivas et al. | Transcriptomic and genetic profiling in a spontaneous non-human primate model of hypertrophic cardiomyopathy and sudden cardiac death | |
| JP2004510442A (ja) | 腫瘍マーカーおよび使用方法 | |
| Poirier et al. | ZNF768 loss amplifies p53 action and reduces lung tumorigenesis in mice | |
| KR102279189B1 (ko) | 대장암의 전이 치료용 약학적 조성물 | |
| US20230383360A1 (en) | Biomarkers for predicting responsiveness to mek inhibitor monotherapy and combination therapy | |
| US20230304102A1 (en) | Biomarkers for predicting responsiveness to shp2 inhibitor therapy | |
| Raven et al. | Hepatocyte identity and zonal position determine tumourigenic potential of mutant β-catenin | |
| 이광훈 | Adult-Type IDH-Mutant Diffuse Gliomas: A Comprehensive Study of Genetic Landscapes, Methylation Profiling, and Prognostic Markers | |
| Keng et al. | A conditional transposon-based insertional mutagenesis screen for hepatocellular carcinoma-associated genes in mice |